Skip to main content

Table 3 Dosimetric changes in different target volumes

From: Determining appropriate timing of adaptive radiation therapy for nasopharyngeal carcinoma during intensity-modulated radiation therapy

 

Plan-0

Plan-1

Plan-2

Plan-3

Plan-4

Plan-5

PTVnx

      

Dmean (Gy)

71.17 ± 1.49

71.31 ± 1.44

71.41 ± 1.43

71.50 ± 1.40

71.60 ± 1.42

71.61 ± 1.44

  P value

 

0.073

0.004

0.001

<0.001

0.001

 D95 (Gy)

67.40 ± 2.48

67.54 ± 2.32

67.64 ± 2.25

67.86 ± 2.26

68.23 ± 2.04

68.18 ± 2.17

  P value

 

0.404

0.256

0.040

0.004

0.015

 V110 (%)

0.29 ± 0.65

0.30 ± 0.64

0.34 ± 0.75

0.29 ± 0.70

0.31 ± 0.86

0.32 ± 0.88

  P value

 

0.447

0.102

0.990

0.887

0.852

 V95 (%)

95.97 ± 5.06

96.29 ± 4.76

96.68 ± 4.4

97.21 ± 3.77

97.72 ± 3.59

97.48 ± 4.34

  P value

 

0.158

0.032

0.013

0.005

0.027

 HI

1.09 ± 0.03

1.09 ± 0.03

1.09 ± 0.03

1.09 ± 0.03

1.09 ± 0.03

1.09 ± 0.03

  P value

 

0.244

0.244

0.116

0.258

0.678

 CI

0.76 ± 0.24

0.77 ± 0.24

0.78 ± 0.23

0.80 ± 0.22

0.81 ± 0.22

0.82 ± 0.21

  P value

 

0.141

0.044

0.005

0.004

0.004

PTVnd

      

Dmean (Gy)

71.60 ± .08

71.51 ± 1.08

71.56 ± 1.12

71.68 ± 1.08

71.73 ± 1.25

71.81 ± 1.22

  P value

 

0.134

0.634

0.334

0.312

0.090

 D95 (Gy)

66.43 ± 3.16

66.88 ± 3.31

66.89 ± 3.27

67.03 ± 3.27

67.27 ± 3.98

67.60 ± 3.57

  P value

 

0.093

0.116

0.025

0.061

0.011

 V110 (%)

0.74 ± 1.43

0.70 ± 1.29

0.71 ± 1.37

0.74 ± 1.45

0.8 ± 1.66

0.76 ± 1.65

  P value

 

0.528

0.386

0.984

0.984

0.902

 V95 (%)

95.09 ± 4.56

96.02 ± 4.21

96.02 ± 4.43

96.09 ± 4.47

96.66 ± 5.44

96.75 ± 5.85

  P value

 

0.066

0.034

0.050

0.010

0.033

 HI

1.10 ± 0.04

1.10 ± 0.04

1.10 ± 0.04

1.10 ± 0.04

1.10 ± 0.03

1.10 ± 0.03

  P value

 

0.282

0.159

0.056

0.186

0.150

 CI

0.80 ± 0.20

0.79 ± 0.18

0.80 ± 0.18

0.81 ± 0.18

0.82 ± 0.19

0.83 ± 0.18

  P value

 

0.355

0.951

0.244

0.063

0.102

PTV1

      

Dmean (Gy)

68.06 ± 2.22

68.38 ± 2.03

68.52 ± 2.04

68.62 ± 1.96

68.69 ± 2.05

68.74 ± 2.06

  P value

 

0.014

0.001

0.003

0.001

0.001

 D95 (Gy)

60.00 ± 4.12

60.63 ± 3.91

61.04 ± 4.11

61.08 ± 4.33

61.24 ± 4.41

61.20 ± 4.43

P value

 

0.146

0.020

0.004

0.017

0.009

 V95 (%)

95.58 ± 4.23

96.80 ± 2.97

96.90 ± 3.17

96.69 ± 3.73

96.79 ± 3.59

96.93 ± 3.46

  P value

 

0.093

0.071

0.051

0.077

0.019

 HI

1.25 ± 0.03

1.25 ± 0.03

1.25 ± 0.03

1.25 ± 0.03

1.25 ± 0.03

1.25 ± 0.03

  P value

 

0.478

0.706

0.258

0.053

0.086

 CI

0.90 ± 0.07

0.92 ± 0.05

0.93 ± 0.06

0.93 ± 0.05

0.93 ± 0.06

0.93 ± 0.06

  P value

 

0.040

0.038

0.006

0.046

0.008

PTV2

      

Dmean (Gy)

60.21 ± 6.65

59.98 ± 6.73

60.07 ± 6.90

60.10 ± 6.80

60.08 ± 6.94

60.20 ± 6.64

  P value

 

0.071

0.345

0.412

0.379

0.940

 D95 (Gy)

47.47 ± 6.42

46.73 ± 6.12

46.94 ± 6.18

46.89 ± 6.21

46.75 ± 16.1

46.61 ± 6.06

  P value

 

0.008

0.069

0.038

0.020

0.023

 V95 (%)

92.48 ± 0.97

91.39 ± 1.10

91.74 ± 1.12

91.84 ± 0.92

91.56 ± 1.25

91.52 ± 0.52

  P value

 

0.015

0.071

0.088

0.028

0.057

 HI

1.42 ± 0.05

1.42 ± 0.05

1.42 ± 0.05

1.42 ± 0.05

1.42 ± 0.05

1.42 ± 0.05

  P value

 

0.334

0.229

0.167

0.173

0.130

 CI

0.87 ± 0.13

0.86 ± 0.13

0.86 ± 0.13

0.86 ± 0.13

0.86 ± 0.13

0.86 ± 0.13

  P value

 

0.032

0.184

0.271

0.082

0.173

  1. Difference was calculated by comparing Plan-0 and each hybrid plan
  2. Dmean mean dose, D95 dose to 95 % of the volume, V110 percentage of the volume receiving more than 110 % of the prescription dose, V95 percentage of the volume receiving 95 % of the prescription dose, HI homogeneity index, CI conformity index